Literature DB >> 30676118

Practice Implications of Expanded Genetic Testing in Oncology.

Diane M Korngiebel1, Jennifer M Zech2, Amelia Chappelle3, Wylie Burke4, Jan D Carline1, Thomas H Gallagher5, Stephanie M Fullerton4.   

Abstract

Genetic test use in oncology is growing, yet providers' experiences with evolving testing norms and their implications for patient care remain under-explored. In interviews with oncologists and cancer genetics professionals, 22 key informants described the increasing importance of germline results for therapeutic decision-making, preference for ordering tests directly rather than referring, and rapid adoption of cancer gene panels for testing. Implications for informed consent, result interpretation, and patient management were identified. These results suggest concerns raised by the transition of genetic test delivery from cancer genetics professionals to oncologists that must be addressed in practice guidelines and provider training.

Entities:  

Keywords:  Cancer; Clinical practice; Genetic testing; Genomic medicine; Inherited risk

Mesh:

Year:  2019        PMID: 30676118      PMCID: PMC6410730          DOI: 10.1080/07357907.2018.1564926

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  3 in total

Review 1.  Familial/inherited cancer syndrome: a focus on the highly consanguineous Arab population.

Authors:  Fawz S AlHarthi; Alya Qari; Alaa Edress; Malak Abedalthagafi
Journal:  NPJ Genom Med       Date:  2020-02-03       Impact factor: 8.617

Review 2.  Familial/inherited cancer syndrome: a focus on the highly consanguineous Arab population.

Authors:  Fawz S AlHarthi; Alya Qari; Alaa Edress; Malak Abedalthagafi
Journal:  NPJ Genom Med       Date:  2020-02-03       Impact factor: 8.617

3.  Positive experiences of healthcare professionals with a mainstreaming approach of germline genetic testing for women with ovarian cancer.

Authors:  Kyra Bokkers; Ronald P Zweemer; Marco J Koudijs; Sanne Stehouwer; Mary E Velthuizen; Eveline M A Bleiker; Margreet G E M Ausems
Journal:  Fam Cancer       Date:  2021-10-07       Impact factor: 2.446

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.